High Throughput Screening Facility

Triple-negative breast cancer accounts for 10 percent of breast cancer cases in the U.S. annually. As T-cells that normally kill cancer cells often become exhausted and stop, Vanderbilt pharmacologists are seeking chemotherapy or targeted therapy approaches that can enhance the T-cell killing of cancer cells. Read More

Days’ work to identify highly potent and selective 5-HT2B antagonists was recognized by the Rosalind Franklin Society Read More

Gary Sulikowski, Stevenson Professor of Chemistry, was named director of the Vanderbilt Institute for Chemical Biology in 2017. Since then, he has stewarded VICB’s growth and research operations. He shares how VICB has contributed to translational research, some of the research he's most excited about, and what makes Vanderbilt a rare place where powerful collaborative research can achieve its potential. Read More

A drug discovery project to mitigate cardiovascular inflammation headed by Sean Davies and Amanda Doran receives funding injection from the School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation.  Read More